Global Glioma Therapeutics Market 2019-2023
About this market
Strategic alliances to drive growth in the market. Pharmaceutical companies are collaborating to develop medications for the treatment of glioma. These alliances can enhance R&D activities for new drugs for the treatment of glioma. Technavio’ s analysts have predicted that the glioma therapeutics market will register a CAGR of more than 9% by 2023.
Market Overview
Expected approval of late-stage pipeline molecules
As the market is currently experiencing an acute lack of approved therapies, these late-stage pipeline molecules can tap into this unmet demand from the glioma patient pool. Once these molecules are launched during the forecast period, the global glioma therapeutics market should observe strong value growth from these newly launched therapeutics.
Availability of alternative therapies
Despite the availability of medications for the treatment of the glioma, there are several alternative procedures. The high cost, side effects, and long duration of treatment with the available medications are increasing patients’ inclination toward the surgical and radiation treatment options.
For the detailed list of factors that will drive and challenge the growth of the glioma therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including NextSource Biotechnology and Novartis the competitive environment is quite intense. Factors such as the expected approval of late-stage pipeline molecules and the strategic alliances, will provide considerable growth opportunities to glioma therapeutics manufactures. F. Hoffmann-La Roche, Merck Sharp & Dohme, Mylan, NextSource Biotechnology, and Novartis are some of the major companies covered in this report.
PRESS RELEASE
Technavio Announces the Publication of its Research Report – Global glioma therapeutics Market 2019-2023
Technavio recognizes the following companies as the key players in the global glioma therapeutics market: F. Hoffmann-La Roche, Merck Sharp & Dohme, Mylan, NextSource Biotechnology, and Novartis.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the strategic alliances.”
According to the report, one of the major drivers for this market is the expected approval of late-stage pipeline molecules.
Companies Mentioned
F. Hoffmann-La Roche
Merck Sharp & Dohme
Mylan
NextSource Biotechnology
Novartis
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook